scispace - formally typeset
T

Tanja I. Näslund

Researcher at Karolinska Institutet

Publications -  17
Citations -  3828

Tanja I. Näslund is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Immune system & Microvesicles. The author has an hindex of 11, co-authored 17 publications receiving 3530 citations. Previous affiliations of Tanja I. Näslund include Karolinska University Hospital.

Papers
More filters
Journal ArticleDOI

RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5' Phosphates

TL;DR: It is shown that influenza A virus infection does not generate dsRNA and that RIG-I is activated by viral genomic single-stranded RNA (ssRNA) bearing 5′-phosphates, and suggested that its ability to sense 5'-phosphorylated RNA evolved in the innate immune system as a means of discriminating between self and nonself.
Journal ArticleDOI

Toll-like receptor 3 promotes cross-priming to virus-infected cells

TL;DR: It is shown that murine CD8α+ dendritic cells are activated by double-stranded (ds)RNA present in virally infected cells but absent from uninfected cells, which indicates that TLR3 may have evolved to permit cross-priming of CTLs against viruses that do not directly infect dendedritic cells.
Journal ArticleDOI

Dendritic Cell-Derived Exosomes Need To Activate Both T and B Cells To Induce Antitumor Immunity

TL;DR: Proper activation of CD4+ T and B cells needs to be considered when designing cancer vaccines to ensure full potential of the treatment.
Journal ArticleDOI

Exosomes from breast milk inhibit HIV-1 infection of dendritic cells and subsequent viral transfer to CD4+ T cells.

TL;DR: It is proposed that milk exosomes act as a novel protective factor against vertical transmission of HIV-1 by competing with HIV- 1 for binding to DC-SIGN on MDDCs.
Journal ArticleDOI

Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.

TL;DR: Findings show that exosomes loaded with protein antigen and αGC will activate adaptive immunity in the absence of triggering iNKT-cell anergy, supporting their application in the design of a broad variety of cancer immunotherapy trials.